Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Stock Information | RedChip

Processa Pharmaceuticals Inc. (NASDAQ: PCSA)


$0.8475
-0.0166 ( +2.11% ) 12.0K

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Market Data


Open


$0.8475

Previous close


$0.8641

Volume


12.0K

Market cap


$2.71M

Day range


$0.8500 - $0.8900

52 week range


$0.8120 - $7.1400

SEC Filings


Form Type Description Pages Date
8-k 8K-related 15 Nov 06, 2024
10-q Quarterly Reports 51 Oct 30, 2024
8-k 8K-related 15 Oct 02, 2024
4 Insider transactions 1 Sep 18, 2024
4 Insider transactions 1 Sep 18, 2024
4 Insider transactions 1 Sep 18, 2024
4 Insider transactions 1 Sep 18, 2024
8-k 8K-related 16 Aug 28, 2024
10-q Quarterly Reports 53 Aug 13, 2024
4 Insider transactions 1 Aug 02, 2024

Latest News